Humana (NYSE:HUM) PT Raised to $407.00 at TD Cowen

Humana (NYSE:HUM) had its price target increased by TD Cowen from $396.00 to $407.00 in a research note published on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the insurance provider’s stock.

Several other brokerages have also issued reports on HUM. The Goldman Sachs Group decreased their price target on shares of Humana from $450.00 to $385.00 and set a buy rating for the company in a research note on Wednesday, April 3rd. Baird R W raised shares of Humana to a hold rating in a report on Thursday, May 30th. Wells Fargo & Company dropped their price target on shares of Humana from $413.00 to $350.00 and set an overweight rating on the stock in a report on Monday, April 8th. Bank of America raised their price objective on shares of Humana from $342.00 to $376.00 and gave the stock a neutral rating in a report on Monday, May 20th. Finally, Oppenheimer dropped their price objective on shares of Humana from $415.00 to $370.00 and set an outperform rating on the stock in a report on Thursday, April 25th. Fourteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $402.60.

Humana Trading Up 1.6 %

NYSE:HUM opened at $392.63 on Wednesday. The company has a fifty day moving average of $365.66 and a 200 day moving average of $347.02. Humana has a 52 week low of $298.61 and a 52 week high of $530.54. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $47.31 billion, a P/E ratio of 24.45, a P/E/G ratio of 2.27 and a beta of 0.51.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the business posted $9.38 EPS. The firm’s revenue was up 10.7% compared to the same quarter last year. On average, research analysts predict that Humana will post 16.27 earnings per share for the current year.

Institutional Investors Weigh In On Humana

Institutional investors and hedge funds have recently modified their holdings of the stock. Rakuten Securities Inc. bought a new position in shares of Humana during the 4th quarter valued at approximately $25,000. Gradient Investments LLC lifted its holdings in shares of Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 40 shares during the last quarter. Cetera Trust Company N.A purchased a new position in Humana in the fourth quarter worth about $28,000. Private Wealth Management Group LLC purchased a new position in Humana in the fourth quarter worth about $32,000. Finally, CarsonAllaria Wealth Management Ltd. lifted its stake in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.